1. Home
  2. AIRI vs COCP Comparison

AIRI vs COCP Comparison

Compare AIRI & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Industries Group

AIRI

Air Industries Group

HOLD

Current Price

$3.01

Market Cap

14.9M

Sector

Industrials

ML Signal

HOLD

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$1.06

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRI
COCP
Founded
1979
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
13.7M
IPO Year
2013
2011

Fundamental Metrics

Financial Performance
Metric
AIRI
COCP
Price
$3.01
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
45.6K
102.3K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
24.39
54.65
EPS
N/A
N/A
Revenue
$47,921,000.00
$12,712,091.00
Revenue This Year
$6.43
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$0.86
52 Week High
$4.17
$2.19

Technical Indicators

Market Signals
Indicator
AIRI
COCP
Relative Strength Index (RSI) 48.58 46.31
Support Level $3.01 $1.00
Resistance Level $3.13 $1.11
Average True Range (ATR) 0.06 0.06
MACD 0.00 0.01
Stochastic Oscillator 14.29 61.15

Price Performance

Historical Comparison
AIRI
COCP

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: